ConductScience.org, home

Paper36939655

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

Martinez-Zapata MJ and 8 others. Cochrane Database Syst Rev, 2023. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Papers, record 36939655. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36939655

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
PubMed
Journal
Cochrane Database Syst Rev
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Systematic Review
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
4.26
iCite
Revised in PubMed
2025-06-26
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martinez-Zapata MJMaria José
2Salvador IIgnacio
3Martí-Carvajal AJArturo J
4Pijoan JIJosé I
5Cordero JAJosé A
6Ponomarev DDmitry
7Kernohan AAshleigh
8Solà IIvan
9Virgili GGianni

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes MellitusMajor topic
Diabetic RetinopathyMajor topic
Aged
Female
Humans
Male
Middle Aged
Ranibizumab
Vascular Endothelial Growth Factor A
Vitreous Hemorrhage

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Update of25418485Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.https://conductscience.org/library/papers/25418485

Source PubMed

Download CSV of comments and corrections

References170

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130905643Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.Ophthalmology2019https://conductscience.org/library/papers/30905643PubMed
23802833Meta-analysis in clinical trials.Control Clin Trials1986https://conductscience.org/library/papers/3802833PubMed
319668420Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy.Clin Ophthalmol2008https://conductscience.org/library/papers/19668420PubMed
429135802PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial.Retina2019https://conductscience.org/library/papers/29135802PubMed
52062513
Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.
Ophthalmology1991https://conductscience.org/library/papers/2062513PubMed
630834517Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.Cochrane Database Syst Rev2019https://conductscience.org/library/papers/30834517PubMed
726630313INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.Retina2016https://conductscience.org/library/papers/26630313PubMed
82866759Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.Arch Ophthalmol1985https://conductscience.org/library/papers/2866759PubMed
92684072Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?Arch Intern Med1989https://conductscience.org/library/papers/2684072PubMed
1019699531Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.Ophthalmology2009https://conductscience.org/library/papers/19699531PubMed
1111549592Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.Am J Pathol2001https://conductscience.org/library/papers/11549592PubMed
1220606024Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy.Br J Ophthalmol2010https://conductscience.org/library/papers/20606024PubMed
1333631120Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis.Can J Ophthalmol2021https://conductscience.org/library/papers/33631120PubMed
1435257962Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy.Ophthalmol Retina2022https://conductscience.org/library/papers/35257962PubMed
1523370902Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.JAMA Ophthalmol2013https://conductscience.org/library/papers/23370902PubMed
1611126403Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.Diabetologia2000https://conductscience.org/library/papers/11126403PubMed
1727034822A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.J Ophthalmol2016https://conductscience.org/library/papers/27034822PubMed
1828492920
Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
JAMA Ophthalmol2017https://conductscience.org/library/papers/28492920PubMed
1916508426Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.Retina2006https://conductscience.org/library/papers/16508426PubMed
2013129861Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.Ophthalmology2003https://conductscience.org/library/papers/13129861PubMed

See all 170 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42911229The role and mechanism of the miR-137 regulatory axis in diabetic retinopathy.Graefes Arch Clin Exp Ophthalmol2026https://conductscience.org/library/papers/42911229PubMed
42899182
Comparison of the efficacy and safety of conbercept plus panretinal photocoagulation versus panretinal photocoagulation alone for proliferative diabetic retinopathy: A multicenter, prospective, randomized controlled study.
Adv Ophthalmol Pract Res2026https://conductscience.org/library/papers/42899182PubMed
42808830L-Threonic Acid Inhibits Pathological Retinal Neovascularization by Modulation of CCL3-CCR5 Signaling Pathway.Invest Ophthalmol Vis Sci2026https://conductscience.org/library/papers/42808830PubMed
42226292FTO-modulated m6A demethylation and upregulation of KIF11 mRNA promotes retinal microvascular dysfunction in diabetic retinopathy.J Transl Med2026https://conductscience.org/library/papers/42226292PubMed
41721853The CAPA framework: a conceptual model integrating corrective and preventive strategies for retinal ischemia and neovascularization.Graefes Arch Clin Exp Ophthalmol2026https://conductscience.org/library/papers/41721853PubMed
41601934Antibody-based therapeutics and therapeutic development for diabetic retinopathy: targeting VEGF, Ang/Tie, and inflammatory pathways.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41601934PubMed
41453592Elevated Retinal Neovascularization on Widefield Optical Coherence Tomography Angiography Predicts Complications in High-Risk Proliferative Diabetic Retinopathy.Am J Ophthalmol2026https://conductscience.org/library/papers/41453592PubMed
41190783Single-Cell RNA Sequencing of Retina Reveals Nna1 Upregulation in Myopic Diabetic Retinopathy as a Protective Factor Against Diabetic Damage.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41190783PubMed
41148385
Efficacy of intravitreal injection of anti-vascular endothelial growth factor as an adjunctive treatment for proliferative diabetic retinopathy before pars plana vitrectomy: a systematic evaluation and meta-analysis.
Int Ophthalmol2025https://conductscience.org/library/papers/41148385PubMed
41113340Integrative Management of High-Risk Proliferative Diabetic Retinopathy: Precision Diagnostics via Ultra-Widefield Imaging and Therapeutic Strategies.Diabetes Metab Syndr Obes2025https://conductscience.org/library/papers/41113340PubMed
40989161Petunidin attenuates lipopolysaccharide-induced retinal microglia inflammatory response in diabetic retinopathy by targeting OGT/NF-κB/LCN2 axis.Open Med (Wars)2025https://conductscience.org/library/papers/40989161PubMed
40891775Sustained Benefit of Short-Term Levodopa Treatment on Inner Retinal Function in Patients With Diabetes.Transl Vis Sci Technol2025https://conductscience.org/library/papers/40891775PubMed
40688778Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection.Int J Ophthalmol2025https://conductscience.org/library/papers/40688778PubMed
40534817Association between findings in nailfold capillaroscopy and diabetic retinopathy: a systematic review and Meta-analysis.Int J Ophthalmol2025https://conductscience.org/library/papers/40534817PubMed
40385017Predictive value of liver and kidney function and bone metabolism markers for postoperative outcomes in diabetic retinal surgery.Am J Transl Res2025https://conductscience.org/library/papers/40385017PubMed
40367061Targeting long non-coding RNA RP11-502I4.3 inhibits the trend of angiogenesis in diabetic retinopathy.PLoS One2025https://conductscience.org/library/papers/40367061PubMed
40253339Peptides based on the interface of hnRNPA2B1-transthyretin complex repress retinal angiogenesis in diabetic retinopathy.J Transl Med2025https://conductscience.org/library/papers/40253339PubMed
40164888The Role of Non-coding RNAs in Diabetic Retinopathy: Mechanistic Insights and Therapeutic Potential.Mol Neurobiol2025https://conductscience.org/library/papers/40164888PubMed
39430009Vascular endothelial growth factor/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy.Int J Ophthalmol2024https://conductscience.org/library/papers/39430009PubMed
39141830Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.ACS Nano2024https://conductscience.org/library/papers/39141830PubMed

See all 24 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36939655

GET https://conductscience.org/api/papers/v1/36939655/references?page=2